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ABSTRACT
This report describes the first Brazilian equine herpesvirus type 1 (EHV-1) isolation from a
single fatal equine herpes myeloencephalopathy case in a mare. The isolation of EHV-1 was
confirmed from the first passage of cerebrospinal fluid (CSF) sample in Vero cells by PCR and virus
neutralization assay.  As virus isolation from CSF is unlikely to be successful, as has been shown
in several case reports, this circumstantial evidence suggests that the neurological disease was
caused by particularly neurovirulent strain of EHV-1.
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RESUMO
PRIMEIRO ISOLAMENTO NO BRASIL DE HERPESVIRUS EQÜINO TIPO 1 EM UM CAVALO
COM DOENÇA NEUROLÓGICA. O presente relato refere-se ao primeiro isolamento no Brasil do
herpesvírus eqüino tipo 1 (HVE-1) proveniente de um caso clínico de mieloncefalopatia herpética
em uma égua, que evoluiu para o óbito. O isolado do HVE-1, denominado 07/05, foi obtido a partir
de uma amostra de líquor na primeira passagem em células Vero, confirmando-se sua identidade
pela PCR e pela prova de neutralização viral. Como o isolamento viral a partir do líquor
geralmente não é bem sucedido, conforme demonstrado em vários relatos de casos, o presente
achado sugere que a doença neurológica foi causada por uma amostra particularmente
neurovirulenta de HVE-1.
PALAVRAS-CHAVE: Herpesvírus eqüino tipo 1, HVE-1, mieloencefalopatia, líquor, isolamento
viral
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Equine herpesvirus type 1 (EHV-1) is an important
pathogen and has been responsible for causing four
recognized clinical syndromes in horses throughout
the world: upper respiratory disease in young horses,
abortion in late gestation, perinatal foal mortality,
and occasionally neurological disorders (REED &
TORIBIO, 2004). Infection may involve a single animal
or be associated with large outbreaks of disease.
The first isolation of EHV-1 in Brazil was
recorded in 1966 from an equine aborted fetus
(N ILSSON; CORREA,  1966). Although EHV-1 is
ubiquitous in the horse populations, there has been
no report of confirmed virus isolation or detection
from nervous tissue or cerebrospinal fluid (CSF) of
equine neurological cases in Brazil (CARVALHO et al.,
2000; GOEHRING et al., 2006).
The EHV-1 neurological disease, also known as
equine herpes myeloencephalopathy (EHM), may be
a result of hypoxic damage to the central nervous
system (CNS) secondary to vasculitis and thrombosis
rather than direct neurologic injury by the virus.
Consequently, in concordance with the
pathophysiology of the disease, attempts to isolate the
virus from the CSF or CNS tissue are seldom successful
(PELLEGRINI-MASINI; LIVESEY, 2006).
Nevertheless, a definitive diagnosis of EHM can
only be supported by the following laboratory tests: 1)
EHV-1 isolation from CSF or brain tissue; 2) identification
of viral particles, inclusions, antigen, or nucleic acid in
CNS tissue (REED; TORIBIO, 2004; DAVIS; TYLER, 2005).
Interestingly, EHM outbreaks have been reported
worldwide with increasing frequency and intensity
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in recent years.  The emergence of hypervirulent
neuropathogenic EHV-1 strains has been a cause of
concern (STUDDERT et al., 2003; NUGENT et al., 2006).
This report describes the first Brazilian EHV-1
isolation from a single fatal EHM case of a mare at an
equestrian facility housing 10 horses.
On 5 May 2005, an 8-year-old Mangalarga breed
mare from a riding school in Ribeirão Pires County
(Sao Paulo State, Southeastern Brazil) was examined
by a private veterinarian. At that time, the animal was
inappetent, lethargic, depressed, and reluctant to move.
There were no reports of respiratory disease, stillborn,
abortion or neurological disease in-contact horses.  In
addition, all the horses in the riding school were
vaccinated annually against eastern and western
encephalomyelitis, rabies and tetanus; however, none
of them was vaccinated against EHV-1 or EHV-4.
Ten days later, the mare showed deterioration
with weakness and paresis of the hind limbs.
Furthermore, complete paralysis and lateral
recumbency developed within the following 24 hours,
being the animal unable to stand by itself.
Nevertheless, on the further neurological examination,
the cranial nerves were normal, as well as there were
no signs of cauda equine syndrome, such as, urinary
incontinence, hypotonia of tail or anus.  Because the
prognosis seemed hopeless due to progressive
neurologic signs that were not responding to
aggressive treatment (supportive nursing, nutritional
care, and reduction of CNS inflammation), the animal
was euthanized.
The acute progressive nervous signs observed in the
present case report could be confused with those observed
in equine encephalomyelitis or rabies viruses infection.
Nevertheless, further laboratory investigations were
negative for equine encephalomyelitis and rabies. At
necropsy, no gross abnormalities were observed.
Brain and CSF from atlanto-occipital site were
submitted to EHV-1 isolation.  Both samples were
inoculated on Vero cells. EHV-1 identification was
performed by virus neutralization test (SAXEGAARD,
1966) and by polymerase chain reaction (PCR).
One mL of the clinical samples (20% w/v brain
tissue or CSF) was inoculated onto monolayers of
Vero cells at 37° C for 1 hour. At the end of the
attachment period, cell monolayers were rinsed, refed
with 6 mL of maintenance media (Eagle’s minimal
essential medium - EMEM supplemented with 200
U/mL penicillin, 200 mg/mL streptomycin, and 50
U/mL nystatin) and incubated at 37° C. Cell cultures
were examined daily for 7 days for the appearance of
characteristic cytopathic effect (CPE) of herpesvirus
(rounding, refringent cells, similar to brunches of
grapes and syncytia formation). One passage was
used routinely for all cases and additional passages
(maximum three) were used when primary isolation
was unsuccessful. Lack of CPE after three passages in
these cultures was interpreted as a negative test.
For seroconfirmation of EHV-1 identity, the
neutralization test was performed with a
hyperimmune polyclonal antiserum against EHV-1
(titer 1:512) that neutralize 100 TCID50 of EHV-1
Brazilian A4/72 strain.  Serial twofold dilutions of
EHV-1 isolate was prepared and mixed with an equal
volume (25 mL) containing positive and negative serum
controls.  The virus and serum mixtures were incubated
for 1 hour at 37° C. The mixtures were then added with
100 mL of the prepared Vero cell suspension (25 x 103
cells/well) in MEM with 10% fetal bovine serum. The
inoculated plates, after incubation at 37° C in 5% CO2
atmosphere for three days, were examined daily for
presence of CPE. Wells were classified as positive for
the virus neutralization test if 100% of the cell
monolayer remained intact (no CPE). The endpoint
titration was defined as the highest dilution of each
sample that inhibited viral CPE.
DNA extraction of the isolate named 07/05 was
conducted following a method described elsewhere
(CHOMCZYNSKI, 1993). PCR was performed using a pair
of specific oligonucleotide primers (P5 forward primer
5’-ATG TCT ACC TTC AAG CTT-3’ and P6 reverse
primer 5’-TTA CGG AAG CTG GGT ATA-3’) derived
from EHV-1 glycoprotein D gene region (GALOSI et al.,
2001). Amplification conditions were performed in a
reaction mixture of total volume 50 mL containing 0.5 mg
of DNA sample, 0.5 mM of each primer, 0.2 mM of each
dNTP mixture, 2.5 units of Taq DNA polymerase
platinum (Invitrogen Brasil Ltda), 1 ´  PCR buffer (20
mM of Tris-HCl pH 8.4, 50 mM of KCl), 1.5 mM of
MgCl2 and ultra-pure water QS. Amplification was
carried out in a thermal cycler (Eppendorf Mastercycler
Gradient PTC-200, Eppendorf AG) under the following
conditions: DNA template was initially denatured at
94° C for 5-min followed by 35 cycles of 1-min
denaturation at 94° C, 1 min primer annealing at 50°
C and 1-min extension at 72° C. Lastly, the reaction
was completed in a 6-min final extension step at 72°
C. Amplified PCR product was analyzed by horizon-
tal electrophoresis (100V for 25 min) in 1.5% agarose
gel and visualized by 0.5 mg/mL ethidium bromide
under UV light. A positive control (purified DNA from
EHV-4 Brazilian A4/72 strain) and a negative control
(ultra-pure water) were included with each PCR assay.
After purification of the amplified DNA fragments
(1,208 base pairs) (GFX PCR DNA and Gel Band
Purification Kit, GE Healthcare Limited), bidirectional
cycle sequencing was performed with BigDye
Terminator Cycle Sequencing Kit (Applied
Biosystems) according to the manufacturer’s
instructions. The sequence reaction products were
analyzed on an automatic ABI Prism 377 DNA
sequencer (Applied Biosystems).
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The sequence quality analysis was examined by
Phred program (http://asparagin.cenargen.embrapa.
br/phph/). The lower threshold of acceptability for
the generation of consensus sequences was set at a
Phred score of 20 for each base. After that, the consensus
sequence was assembled using CAP contig assembly
program and the alignment was obtained with
homologous sequence from EHV-1 reference strain
Ab4 (GenBank access number AY665713) using the
ClustalW method of the software BioEdit version
7.0.5.3 (HALL, 1999).
In the first passage of CSF sample in Vero cells,
EHV-1 isolate 07/05 was recovered within 24 hours
and its identity was confirmed by PCR and virus
neutralization assay; however, the brain material
was negative after three passages in Vero cells.  In Vero
cells, the virus reached an infectivity titer of 102.7
TCID50/25 mL. The failure to isolate EHV-1 from brain
may be due to the lower sensitivity of conventional
virological methods (CINQUE et al., 2003). Alternatively,
neural cells may be low in number and segmental in
distribution.  It can be assumed that the time lapse
between acute virus replication and horse death may
be critical for identification of EHV-1 in neural tissues.
Other factors, such as the conservation of the material
obtained for virus isolation, should play an additional
role (SCHULTHEISS et al., 1997).
Nevertheless, as virus isolation from CSF is unlikely
to be successful, as has been shown in several case
reports, this circumstantial evidence suggests that the
neurological disease was caused by particularly
neurovirulent strain of EHV-1 (PELLEGRINI-MASINI &
LIVESEY, 2006). NUGENT et al. (2006) identified a single
nucleotide polymorphism in the viral DNA
polymerase enzyme gene (ORF30) that showed highly
statistically significant correlation with paralytic
disease severity during an EHM outbreak.  Therefore,
additional studies have been needed to indicate
whether mutant strains of EHV-1 have occurred in
Brazil.
Employing gD primers, both original unprocessed
CSF sample and cultured Brazilian EHV-1 isolate 07/
95 were positive by PCR.  Furthermore, this amplified
gD region was sequenced (GenBank accession
number EU052212). Glycoprotein D sequences of 07/
05 isolate showed 100% of identity when compared
with corresponding sequence of EHV-1 reference strain
Ab4, suggesting that among EHV-1 strains the gD
gene is highly conserved.  In fact, and in spite of
dramatic differences in the virulence and tissue
tropism, the examination of this highly conserved
region could not explain the neuropathogenicity of
the 07/05 isolate.
Previous EHM reports have not very detailed
molecular analysis as here (THEIN et al., 1993). In
human medicine, the use of molecular techniques has
clearly improved the diagnosis and clinical
management of viral CNS infections (CINQUE et al.,
2003). The positive CFS PCR result indicated the
presence of viral nucleic acid and was a marker of
recent or ongoing active CNS EHV-1 infection (DE
BIASI et al., 2002). Sequencing DNA techniques have
enabled precise characterization of viral genome
following their recovery in the CSF. In conclusion, an
EHV-1 isolate was obtained from the CSF of a horse
with neurological disorders that is identical to strains
isolated elsewhere, showing that CSF can be used as
a sample for EHV-1 detection.
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